Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05433116
Title Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Erlangen-Nuernberg Medical School
Indications

hypopharynx cancer

supraglottis squamous cell carcinoma

oral squamous cell carcinoma

oropharynx cancer

Therapies

Lenvatinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.